After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...
In case you've faced some hurdles solving the clue, Dynamic in which you might be coy and playful for fun, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your ...
Mixpanel, a global leader in digital analytics, today announced the launch of Metric Trees, a digital analytics capability that helps companies bring clarity, alignment, and accountability to their ...
Abstract: Multi-cloud is a promising paradigm due to its advantages such as avoiding vendor lock-in and optimising costs. This article focuses on dynamic flexible workflow scheduling with minimum ...
Abstract: Students often struggle to grasp abstract concepts of recursion and dynamic programming as they experience cognitive overload when tracking multiple recursive calls. Additionally, they often ...
Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...
Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at ...
Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...